Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for Ascendis Pharma A (ASND) over the last 7 years, with Q4 2025 value amounting to $67.8 million.

  • Ascendis Pharma A's Other Non-Current Liabilities fell 669.17% to $67.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $67.8 million, marking a year-over-year decrease of 669.17%. This contributed to the annual value of $65.8 million for FY2025, which is 942.06% down from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's Other Non-Current Liabilities is $67.8 million, which was down 669.17% from $56.5 million recorded in Q3 2025.
  • Ascendis Pharma A's 5-year Other Non-Current Liabilities high stood at $72.6 million for Q4 2024, and its period low was $14.1 million during Q1 2022.
  • Its 5-year average for Other Non-Current Liabilities is $37.3 million, with a median of $34.3 million in 2021.
  • In the last 5 years, Ascendis Pharma A's Other Non-Current Liabilities soared by 6391.13% in 2024 and then tumbled by 669.17% in 2025.
  • Ascendis Pharma A's Other Non-Current Liabilities (Quarter) stood at $34.3 million in 2021, then fell by 4.75% to $32.6 million in 2022, then soared by 35.75% to $44.3 million in 2023, then surged by 63.91% to $72.6 million in 2024, then dropped by 6.69% to $67.8 million in 2025.
  • Its last three reported values are $67.8 million in Q4 2025, $56.5 million for Q3 2025, and $45.2 million during Q2 2025.